Skip to main content

Hogge Gary S.'s Form 4 filing

Lineage Cell Therapeutics, Inc.LCTX · filed Dec 30, 2021

Accession no.
0001493152-21-032897
Filed
Dec 30, 2021
Trade date
Dec 28-29, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 7 non-derivative transactions and 4 derivative transactions. Open-market sales total $1.32M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hogge Gary S.CIK 0001771711Officer (SVP,Clinical & Medical Affairs)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 28, 2021Common Shares, no par valueMOption exerciseAcquired+185,000$0.69+$127,650213,445Direct
Dec 28, 2021Common Shares, no par valueMOption exerciseAcquired+236,899$2.11+$499,856.89450,344Direct
Dec 28, 2021Common Shares, no par valueMOption exerciseAcquired+79,689$1.14+$90,845.46530,033Direct
Dec 28, 2021Common Shares, no par valueSSaleDisposed−501,588$2.45F1−$1,228,890.628,445Direct
Dec 29, 2021Common Shares, no par valueMOption exerciseAcquired+9,250$0.69+$6,382.537,695Direct
Dec 29, 2021Common Shares, no par valueSSaleDisposed−9,250$2.49F2−$23,032.528,445Direct
Dec 29, 2021Common Shares, no par valueSSaleDisposed−28,445$2.44F3−$69,405.80Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 28, 2021Common SharesMOption exerciseDisposed−185,000$0.00$0259,000Direct
Dec 28, 2021Common SharesMOption exerciseDisposed−236,899$0.00$010,301Direct
Dec 28, 2021Common SharesMOption exerciseDisposed−79,689$0.00$032,811Direct
Dec 29, 2021Common SharesMOption exerciseDisposed−9,250$0.00$0249,750Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.40 to not more than $2.53. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

F2

The 9,250 shares sold on 12/29/21, were all sold at a transaction price of $2.49.

Referenced by the price of 1 transaction in Table I.

F3

The price reported is a weighted average. These shares were sold in multiple transactions at prices ranging from $2.42 to not more than $2.52. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Referenced by the price of 1 transaction in Table I.

Remarks

Exhibit 24 - Power of Attorney

Read the full filing on SEC EDGAR (opens in a new tab)